The dual inhibition of PD-L1 and LAG-3 using the BsAb IBI323 enhances T-cell-mediated anti-tumor responses beyond the efficacy of monotherapies or combination therapies, indicating a synergistic mechanism of immune activation. This evidence concerns the gene LAG3 and neoplasm.